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power of the high-resolution phenotyping afforded by
zebrafish and the value of the large-scale databases
linking phenotype and genotype in this organism. As
these databases progress toward completeness, the
validity of the approach will continue to increase. Al-
though this strategy is unlikely to be universally effec-
tive, the fumagillin success makes a strong case for
considering the approach as a potent, albeit ‘‘nonca-
nonical,’’ path to deciphering small-molecule mecha-
nisms of action.
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A paper published in the September 8 issue of Cell [1]
describes a generally applicable approach for chemi-
cal control of protein stability, with potential for broad
use in chemical genetics.
An oft-stated goal for chemical biology is to provide new
tools for analyzing gene and protein function that com-
plement classical genetics. This aspiration, encapsu-
lated in the phrase ‘‘chemical genetics,’’ is increasingly
being fulfilled as chemical probes are used to inhibit pro-
teins of interest and generate chemically-induced alleles
of protein function [2].
What chemistry has to offer genetics above all else is
the dimension of time [2, 3]. Essentially, small molecules
can be used to effect ‘‘instant mutagenesis’’ by specifi-
cally inhibiting (or activating) a protein of interest in real
time. By contrast, generation of knockout mice to look at
the functional consequences of protein loss is a slow
process, often stymied by embryonic lethality or con-
founding compensatory changes in gene expression.
RNAi [4] provides a new way to knock down protein
function, but is still slower to take effect as it does not di-
rectly target the protein. Thus, chemical approaches
have the potential to illuminate otherwise invisible areas
of biology.
Unfortunately, as a field we are not yet at a point where
we can routinely generate suitable chemical inhibitors
for every protein of interest. This is particularly true if
in vivo studies are contemplated, meaning that the addi-
tional hurdle of pharmacology needs to be cleared. An
alternative strategy is to ‘‘tag’’ a protein of interest in such
a way that it can be targeted by a generic ligand—forexample by fusing it to a heterologous protein [3]. This
powerful approach in principle allows any protein of in-
terest to be chemically manipulated in real time without
the need for a specific inhibitor. ‘‘Tagging’’ strategies
have both drawbacks and advantages. They assume
that protein function is unaffected by the tag, and they
also require genetic steps to express the modified pro-
tein in cells. In addition, because endogenous, unmodi-
fied protein molecules will be unaffected by the generic
ligand, either the protein of interest needs to have a dom-
inant effect, or the study needs to be performed in the
background of a knockout of the endogenous protein.
On the other hand, since the effects of the small molecule
are restricted to cells expressing the tagged protein,
these approaches can often be more precise than the
use of a direct chemical inhibitor.
Many successful ‘‘tagging’’ strategies have been de-
scribed [3]. For example, dimeric small molecules can
be used to inducibly dimerize tagged proteins, allowing
study of proteins and pathways controlled by protein-
protein associations [5, 6]. Expression of protein kinases
that are modified to bind certain inhibitors uniquely has
allowed very precise delineation of the roles of individual
kinases and substrates in cell biology [7]. Several of
these technologies have ‘‘crossed over’’ from the field
of chemical biology to become established mainstream
biological research tools. However, they are generally
restricted to subsets of proteins that share a certain
mechanism of action. A truly versatile technology for
chemically regulating protein function, generally appli-
cable to any protein, is a highly desirable goal.
Such an approach was described a few years ago by
Stankunas et al. [8], who developed a system for con-
trolling protein stability—a shared property essential to
all proteins (see Figure 1). These authors exploited the
chance observation that a certain mutated protein
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to any protein to which it is fused. This instability can be
rescued by addition of rapamycin or a specific analog
called Ma-rap, which bind to FRB* in complex with en-
dogenous protein FKBP. The investigators showed
that fusing FRB* to a protein of interest targets it to the
proteasome, whereas the ligand-bound FRB* is spared.
Thus, this ‘‘stability switch’’ allows the induction of a
brief, defined period of protein function and is in princi-
ple applicable to any protein.
Unfortunately this prototype system is limited by is-
sues associated with the ligands. Rapamycin is a highly
bioactive molecule whose anti-proliferative effects will
often confound studies of cellular function; Ma-rap lacks
these effects but cannot be used in mice due to poor
pharmacology [8, 9]. In principle one could engineer
the system to work with different rapamycin analogs
[6, 9]. Instead, in their Cell paper, Banaszynski et al. [1]
have devised a more versatile and broadly applicable
stability switch based on a different ligand-protein
pair. They turned to FKBP, a small chaperone-like pro-
tein that has proved to be fertile ground for both protein
engineers and chemical biologists. Particularly useful
are ligands that have been engineered to bind only to a
specific mutant, F36V, rather than the wild-type protein,
as these ligands are physiologically inert and have been
widely used in vivo [10].
Using F36V as a starting point, Banaszynski et al. [1]
pummeled the normally stable protein by random muta-
genesis and used a clever selection scheme involving N-
terminal fusion to the fluorescent protein YFP and
rounds of flow cytometry to identify destabilizing mu-
tants. A broad panel of such mutants was obtained,
each of which confer different levels of destabilization
and therefore rates of degradation. All were rescuable
by Shld1, a specific monomeric F36V ligand [11] de-
signed to be cell permeant—addition of Shld1 induced
protein accumulation and prevented degradation by
the proteasome. In an impressive demonstration of the
‘‘tuneability’’ of the new system, protein function (in
this case YFP fluorescence) was iteratively adjusted
through several levels between zero and 100% and
back again over the course of a week by exposing cells
to different concentrations of Shld1.
Figure 1. Control of Protein Stability Using Small Molecules and
a Destabilizing Protein Tag
A protein of interest (rectangle) is fused to a destabilizing protein tag
(horseshoe), leading to proteolytic elimination of the fusion protein.
Addition of a tag-specific ligand stabilizes the tagged protein, lead-
ing to its accumulation, which can be reversed by removal or break-
down of the ligand.Banaszynski et al. went to considerable lengths
to establish the generality of their approach. They
identified separate mutants optimized to function as
C-terminal fusions, for cases where N-terminal fusion
would interfere with protein function. They showed that
the system was able to control the stability of 14 dif-
ferent proteins of disparate classes, including mem-
brane proteins, and to function in multiple cell lines.
They also validated that it could be used to bring cel-
lular phenotypes under chemical control by inducing
reversible changes in cell morphology through Shld1-
mediated control of three different cell cycle regulatory
proteins.
An important additional experiment reported by the
authors is a comparison of their approach with RNAi (al-
though not, unfortunately, with the same target protein).
Control with the stability system achieved a faster (max-
imal at 4 versus 48 hr) and more complete knockdown of
protein expression than transfection with synthetic
siRNA. These comparisons are rarely done with new
chemical genetic tools, but are important if these new
approaches are to be understood and embraced by
the broader cell biology research community.
A crucial next step will be a demonstration of true
functionality and versatility in the in vivo setting. Here
the omens are good, since F36V ligands have been suc-
cessfully used in dozens of studies in mice, rats, and
nonhuman primates [6], and even humans [12]. It should
be noted that most of these studies used dimeric li-
gands, which would likely be inappropriate for use in
controlling stability. Shld1-like monomeric ligands
have been used in some mouse studies [13], but tweak-
ing may be required to identify a compound (and formu-
lation) with optimal pharmacokinetics, metabolism, and
tissue distribution for use with the stability switch. How-
ever, it is likely that this new ‘‘tagging’’ system will prove
broadly applicable to the analysis of protein function
both in vitro and in experimental animals.
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